J. Michael Ryan is the Chief Medical Officer at Asceneuron. With over 15 years of Central Nervous System (CNS) clinical research experience, Michael is responsible for advancing Asceneuron’s pipeline of innovative small molecules and progressing tau modifiers through the clinic.   Michael joined Asceneuron from Novartis Pharmaceuticals Corporation, where he was Vice President in the Neuroscience Development Franchise and Therapeutic Area Head for Neurodegeneration for five years. At Novartis, he worked on the clinical development strategy and led programmes in a number of CNS indications including Alzheimer’s disease, Parkinson’s disease and Schizophrenia. He has also held a number of senior clinical research and development positions at several multi-national companies including Pfizer, Wyeth Research, and MSD Research Laboratories (known as Merck Research Laboratories in the United States). Michael completed training in geriatric psychiatry and neuropsychiatry at Dartmouth Medical School and has published over 30 scientific articles on neurodegenerative diseases. He has held academic positions at Dartmouth Medical School and the University of Rochester, where he co-directed the Geriatric Neurology & Psychiatry Clinic until 2004. Michael holds an M.D. in Medicine from the Medical University of South Carolina and a B.S. in Biology from Georgetown University

 he worked on the clinical development strategy and led programmes in a number of CNS indications including Alzheimer’s disease, Parkinson’s disease and Schizophrenia